Literature DB >> 16740750

The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma.

Annette Paschen1, Norbert Arens, Antje Sucker, Karin M Greulich-Bode, Ester Fonsatti, Annunziata Gloghini, Sandra Striegel, Nicole Schwinn, Antonino Carbone, Ralf Hildenbrand, Adelheid Cerwenka, Michele Maio, Dirk Schadendorf.   

Abstract

PURPOSE: Total loss of surface presentation of human leukocyte antigen (HLA) class I molecules, protecting tumor cells from the recognition by cytotoxic host CD8+ T cells, is known to be caused by mutations in the beta2-microglobulin (beta2m) gene. We asked whether abnormalities of chromosome 15, harboring the beta2m gene on 15q21, in addition to beta2m gene mutations, are causative for the HLA class I-negative phenotype of melanoma cells. EXPERIMENTAL
DESIGN: To answer this, we established primary cell lines from the beta2m-negative metastatic melanoma tissues of four different patients and analyzed them for beta2m gene mutations and chromosome 15 aberrations, the latter by loss of heterozygosity analysis, fluorescence in situ hybridization (FISH), and multicolor FISH.
RESULTS: Mutations at the beta2m gene level were detected in all cell lines. The loss of heterozygosity analysis of microsatellite markers located on chromosome 15 in three of the four cell lines pointed to an extensive loss of chromosome 15 material. Subsequent molecular cytogenetic analysis revealed the coexistence of apparently normal and rearranged versions of chromosome 15 in three cell lines whereas the fourth cell line solely showed rearranged versions. Two of the four cell lines exhibited a special type of intrachromosomal rearrangement characterized by FISH signals specific for the subtelomeric region of 15q at both ends of the chromosome and one centromeric signal in between.
CONCLUSIONS: Our data indicate that the complete loss of HLA class I expression in melanoma cells is due to the coincidence of the following mutational events: (a) chromosome 15 instability associated with an extensive loss of genetic material and (b) beta2m gene mutations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16740750     DOI: 10.1158/1078-0432.CCR-05-2174

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

1.  Deciphering the genetic evolution of T-cell resistance in melanoma.

Authors:  Antje Sucker; Annette Paschen
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

Review 2.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

3.  Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.

Authors:  Scott Gettinger; Jungmin Choi; Katherine Hastings; Anna Truini; Ila Datar; Ryan Sowell; Anna Wurtz; Weilai Dong; Guoping Cai; Mary Ann Melnick; Victor Y Du; Joseph Schlessinger; Sarah B Goldberg; Anne Chiang; Miguel F Sanmamed; Ignacio Melero; Jackeline Agorreta; Luis M Montuenga; Richard Lifton; Soldano Ferrone; Paula Kavathas; David L Rimm; Susan M Kaech; Kurt Schalper; Roy S Herbst; Katerina Politi
Journal:  Cancer Discov       Date:  2017-10-12       Impact factor: 39.397

4.  Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors.

Authors:  Isabel Maleno; Natalia Aptsiauri; Teresa Cabrera; Aurelia Gallego; Annette Paschen; Miguel Angel López-Nevot; Federico Garrido
Journal:  Immunogenetics       Date:  2010-11-18       Impact factor: 2.846

Review 5.  Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer.

Authors:  Kosei Yasumoto; Takeshi Hanagiri; Mitsuhiro Takenoyama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-09-13

6.  NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.

Authors:  Tadepally Lakshmikanth; Shannon Burke; Talib Hassan Ali; Silvia Kimpfler; Francesco Ursini; Loredana Ruggeri; Marusca Capanni; Viktor Umansky; Annette Paschen; Antje Sucker; Daniela Pende; Veronika Groh; Roberto Biassoni; Petter Höglund; Masashi Kato; Kazuko Shibuya; Dirk Schadendorf; Andrea Anichini; Soldano Ferrone; Andrea Velardi; Klas Kärre; Akira Shibuya; Ennio Carbone; Francesco Colucci
Journal:  J Clin Invest       Date:  2009-04-06       Impact factor: 14.808

7.  Genetic evolution of T-cell resistance in the course of melanoma progression.

Authors:  Antje Sucker; Fang Zhao; Birgit Real; Christina Heeke; Nicola Bielefeld; Stefan Maβen; Susanne Horn; Iris Moll; Raffaela Maltaner; Peter A Horn; Bastian Schilling; Francesco Sabbatino; Volker Lennerz; Matthias Kloor; Soldano Ferrone; Dirk Schadendorf; Christine S Falk; Klaus Griewank; Annette Paschen
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

Review 8.  [HLA and immune of lung cancer].

Authors:  Huijuan Wang; Qinqin Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-02

9.  Exposure to Melan-A/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS).

Authors:  Frédéric Ebstein; Martin Keller; Annette Paschen; Peter Walden; Michael Seeger; Elke Bürger; Elke Krüger; Dirk Schadendorf; Peter-M Kloetzel; Ulrike Seifert
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379

10.  Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.

Authors:  Antje Sucker; Fang Zhao; Natalia Pieper; Christina Heeke; Raffaela Maltaner; Nadine Stadtler; Birgit Real; Nicola Bielefeld; Sebastian Howe; Benjamin Weide; Ralf Gutzmer; Jochen Utikal; Carmen Loquai; Helen Gogas; Ludger Klein-Hitpass; Michael Zeschnigk; Astrid M Westendorf; Mirko Trilling; Susanne Horn; Bastian Schilling; Dirk Schadendorf; Klaus G Griewank; Annette Paschen
Journal:  Nat Commun       Date:  2017-05-31       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.